Vobarilizumab

For research use only. Not for therapeutic Use.

  • CAT Number: I042212
  • CAS Number: 1628814-88-9
  • Purity: ≥95%
Inquiry Now

Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3].
Vobarilizumab shows a preferential binding affinity for sIL-6R compared with mIL-6R[2].
Vobarilizumab (0-10 nM) blocks the interaction of recombinant hIL-6 to recombinant hsIL-6R[3].
Vobarilizumab (0-100 nM) blocks proliferation of the TF-1 cells[3].
Vobarilizumab (0.4-10 mg/kg, i.v.) inhibits hIL-6-induced inflammation in cynomolgus monkey[3].
Vobarilizumab (0.4-10 mg/kg, i.v.) shows a prolonged exposure through binding to serum albumin in cynomolgus monkeys[3].


Catalog Number I042212
CAS Number 1628814-88-9
Purity ≥95%
Reference

[1]. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759.
 [Content Brief]

[2]. M. Van Roy, et al. FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis. 2013. 72 (3).

[3]. Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135.
 [Content Brief]

Request a Quote